Acceleron Pharma Appoints Dr. Francois Nader To Its Board Of Directors
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors.
“Dr. Nader brings an experienced executive’s knowledge of drug development and commercialization in the rare disease area to our board, and we look forward to his contributions to the company’s future,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
Help employers find you! Check out all the jobs and post your resume.
“Dr. Nader brings an experienced executive’s knowledge of drug development and commercialization in the rare disease area to our board, and we look forward to his contributions to the company’s future,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
Help employers find you! Check out all the jobs and post your resume.